NEFL and Cerebral cortical atrophy: Previous studies have established that longitudinal declines in NfL correlate well with ATN status [35], AD-associated clinical changes [3], and faster rates of decline in cognition and cortical atrophy [36], so it is likely that plasma NfL can serve as a reliable marker for disease-modifying treatments in AD.